Company Profile
Xilio Therapeutics Stock Price, News & Analysis
- Ticker:
- XLO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.27 USD (+1.76%)
Close
Last updated: August 6, 2026
53.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, XLO closed up 1.76% at $9.27. No new same-company headline was identified in the current news window.
Company overview
Tumor-Activated Immunotherapy
Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment.
XTX501
XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.
Masked T-Cell Engagers
Earlier programs include XTX601 targeting CLDN18.2 and a multispecific engager targeting PSMA and STEAP1.
Future catalysts
An IND submission for XTX501 is planned around mid-2026.
A Phase 1 study of XTX501 is expected to begin in the second half of 2026.
Initial Phase 1 data in metastatic non-small cell lung cancer are expected in the second half of 2027.
Recent news
- 01
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Xilio Therapeutics
- 02
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Source: Xilio Therapeutics
- 03
- 04
- 05
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
Source: Xilio Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xilio Therapeutics (XLO)?
Xilio Therapeutics (XLO) most recently closed at 9.27 USD, a +1.76% move versus the previous session.
What is the market cap of Xilio Therapeutics (XLO)?
Xilio Therapeutics currently has a market capitalization of 53.9M USD on BioPharmSignal.
What does Xilio Therapeutics do?
Tumor-Activated Immunotherapy Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment. XTX501 XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors. Masked T-Cell Engagers Earlier programs include...
On which exchange is XLO stock listed?
Xilio Therapeutics (XLO) is associated with NASDAQ, United States, Biopharma.
What is PD-1?
XTX501 XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.
Which conditions is Xilio Therapeutics targeting with PD-1?
Xilio Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Xilio Therapeutics describe recent progress with PD-1?
An IND submission for XTX501 is planned around mid-2026. A Phase 1 study of XTX501 is expected to begin in the second half of 2026. Initial Phase 1 data in metastatic non-small cell lung cancer are expected in the second half of 2027.
What is IL-2?
XTX501 XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.